Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Sundar Jagannath
October 24, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

Related Content

AUTOPLAY
Total Health Conferencing

2021 ASCO Virtual Direct™ Highlights San Francisco

Sat, Jul 31, 2021
13:44
SOHO Italy 1st School of Multiple Myeloma

MRD Assessment Within the Bone Marrow of MM: Immunoglobulin Genes as Marke…

Feat. C. Terragna
22:16
SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of the Dise…

Feat. N. Bolli
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
10:37
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

State of the Art in the Management of Multiple Myeloma: Smoldering Disease…

Feat. K. Shain
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Therapy …

Feat. A. Rosko
22:09
Moffitt Cancer Center

Moffitt Updates on AL Amyloidosis: Primary Systemic Disease Basics, Diagno…

Feat. B. Blue
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
12:44
Bart Barlogie

Clinical Manifestations & Diagnostic Work Up of Myeloma

23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
05:11
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1st Rel…

Feat. B. Derman
13:27
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain
54:04
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

MGUS: Disease Definitions, Diagnostic Approaches and Risk Stratification

Feat. M. Gertz
19:49
Gareth J Morgan

Contemporary Design of MM Treatment: Developing New Therapeutic Endpoints,…